Financial Performance - Net profit attributable to the parent company in 2023 was 1,411,985,024.41 yuan, with a year-end distributable profit of 4,774,244,419.42 yuan[2] - Revenue for 2023 reached 22.59 billion RMB, a 35.95% increase compared to 2022[15] - Net profit attributable to shareholders in 2023 was 1.41 billion RMB, up 9.80% year-over-year[15] - Operating cash flow for 2023 was 4.62 billion RMB, a 17.94% increase from 2022[16] - Total assets at the end of 2023 were 24.14 billion RMB, a 14.74% increase compared to 2022[16] - Basic earnings per share for 2023 was 1.40 RMB, an 11.11% increase from 2022[17] - Weighted average return on equity (ROE) for 2023 was 15.44%, a slight decrease of 0.34 percentage points from 2022[17] - Q4 2023 revenue was 6.70 billion RMB, the highest among all quarters[19] - Non-recurring gains and losses in 2023 totaled 50.47 million RMB, a significant increase from 34.41 million RMB in 2022[21] - Government subsidies in 2023 amounted to 44.93 million RMB, up from 32.82 million RMB in 2022[20] - The company achieved a net profit attributable to shareholders of 1,411.985 million yuan, a year-on-year increase of 11.90%[29] - The company's total revenue reached 22,588.2274 million yuan, a year-on-year increase of 13.59%[29] - The company's total assets increased by 14.74% to 24,136.5392 million yuan[29] - The company's equity attributable to shareholders increased by 14.63% to 9,804.4325 million yuan[29] - The company's weighted average return on equity reached 15.44%[29] - The company's earnings per share were 1.40 yuan[29] - The company's trading financial assets increased by 1,580.67574849 million yuan to 1,630.72088794 million yuan[25] - The company's sales revenue increased by 13.59% and net profit attributable to shareholders increased by 11.90% year-on-year[50] - Revenue for the reporting period was RMB 225.88 billion, a year-on-year increase of 13.59%, with net profit attributable to shareholders of RMB 14.12 billion, up 11.90% year-on-year[58] - Operating income increased by 13.59% to RMB 225.88 billion, driven by same-store sales growth, new store openings, and acquisitions[59] - Operating costs rose by 16.07% to RMB 139.58 billion, primarily due to increased sales volume[59] - Sales expenses increased by 12.49% to RMB 54.87 billion, mainly due to new store openings and promotional activities[59] - R&D expenses grew by 32.56% to RMB 335.5 million, driven by the capitalization of development expenditures[59] - Net cash flow from operating activities increased by 17.94% to RMB 46.24 billion, supported by sales growth and increased use of bills payable[59] - Net cash flow from investing activities decreased by 133.93% to RMB -29.80 billion, mainly due to increased purchases of financial products[59] - Net cash flow from financing activities decreased by 26.45% to RMB -20.93 billion, primarily due to increased rental payments and shareholder dividends[59] - Retail business revenue reached 20.19 billion RMB, accounting for 91.43% of total revenue, with a gross margin of 39.59%, down 0.85% year-over-year[61] - Wholesale business revenue grew by 39.23% to 1.89 billion RMB, with a gross margin of 9.36%, down 0.11% year-over-year[61] - Total revenue increased by 13.91% to 22.08 billion RMB, with a gross margin of 37.00%, down 1.27% year-over-year[61] - Revenue from Chinese and Western medicines grew by 15.93% to 17.09 billion RMB, while traditional Chinese medicine revenue increased by 23.30% to 2.18 billion RMB[61] - Sales costs for retail and wholesale businesses increased by 13.60% and 39.39% respectively, totaling 13.91 billion RMB[63] - Sales expenses rose by 12.49% to 5.49 billion RMB, driven by revenue growth[67] - R&D expenses increased by 32.56% to 33.55 million RMB, with 63.07% of R&D investment being capitalized[68] - The company's operating cash flow increased by 17.94% to RMB 4,623,740,795.60, driven by sales growth and increased bill settlements[72] - Investment cash flow decreased by 133.93% to RMB -2,980,321,075.21 due to increased purchase of financial products[72] - The company's trading financial assets increased by 3,158.50% to RMB 1,630,720,887.94, mainly due to increased purchase of bank financial products[73] - The company's prepayments decreased by 37.25% to RMB 141,493,810.64 due to reduced procurement prepayments[74] - The company's contract liabilities increased by 32.10% to RMB 80,166,931.03 due to increased prepaid stored value cards[74] - The company's total revenue for 2023 reached $12.34 billion, representing a 15% year-over-year growth[120] - Net profit for the year was $1.23 billion, an increase of 20% compared to the previous year[120] - Research and development expenses accounted for 8% of total revenue, amounting to $987 million[120] - The company's e-commerce platform saw a 40% increase in sales, reaching $2.5 billion in 2023[121] - The company's total revenue for 2023 was RMB 225.88 billion, with pharmaceutical sales accounting for RMB 192.75 billion, representing 85.33% of total revenue[200] Dividend and Share Capital - The company plans to distribute a cash dividend of 505,289,898.50 yuan (tax included) and increase share capital by 202,115,959 shares, raising the total share capital to 1,212,695,756 shares[2] - The company distributed a cash dividend of RMB 288,681,972.00 for the 2022 fiscal year, with a cash dividend of RMB 0.40 per share and a capital reserve transfer of 0.40 shares per share[140] - For the 2023 fiscal year, the company plans to distribute a cash dividend of RMB 0.50 per share and a capital reserve transfer of 0.20 shares per share, totaling RMB 505,289,898.50[140][143] - The cash dividend for 2023 accounts for 35.79% of the net profit attributable to shareholders of the parent company[143] - The company granted 390,015 restricted shares to 39 incentive recipients at a price of RMB 18.95 per share in 2023[145] - The company unlocked 2,062,480 restricted shares for 220 incentive recipients in 2023, following the 2022 annual equity distribution[145] - The company granted a total of 141,750 restricted shares to senior executives during the reporting period, with a grant price of 18.95 yuan per share[146] - The total number of restricted shares held by senior executives at the end of the reporting period was 190,750 shares, with a market price of 40.04 yuan per share[146] - Total shares increased by 288,874,867 shares due to capital reserve to share capital conversion, repurchase and cancellation of restricted shares, and granting of restricted shares, resulting in a total of 1,010,579,797 shares at the end of the reporting period[185] - Earnings per share (EPS) for the reporting period was 1.40 RMB, and net asset value per share was 9.70 RMB[185] - The company implemented a capital reserve to share capital conversion, issuing 4 additional shares for every 10 shares held, increasing the total shares to 1,010,386,902 shares[183] - The company repurchased and canceled 104,160 restricted shares, adjusting the total shares to 1,010,282,742 shares[184] - An additional 92,960 restricted shares were repurchased and canceled, further adjusting the total shares to 1,010,189,782 shares[184] - The company granted 390,015 restricted shares to 39 incentive recipients, increasing the total shares to 1,010,579,797 shares[184] - The number of restricted shares at the end of the year was 2,463,695 shares, with 2,062,480 shares released from restrictions during the year[186] Store Expansion and Operations - The company added 3,196 new stores, including 1,613 self-built stores, 559 acquired stores, and 1,024 franchise stores[29] - The company's total number of stores reached 13,250, including 2,986 franchise stores, with a net increase of 2,982 stores[29] - The company operates 13,250 chain pharmacies (including 2,986 franchise stores) in ten provinces and cities[42] - The company added 2,982 new stores during the reporting period[50] - Total number of stores reached 13,250, with a net increase of 2,982 stores in 2023, achieving a compound annual growth rate (CAGR) of 29.69% from 2018 to 2023[51] - The company's total number of stores increased by 2,982 to 13,250, with 214 stores closed or relocated due to optimization and strategic adjustments[78] - The company's store network has grown at a compound annual growth rate of 29.69% over the past five years, with a net increase of 9,639 stores since 2018[79] - The company has 10,264 directly operated stores, with detailed operational efficiency metrics provided[79] - Total number of directly operated stores reached 10,264, with a total operating area of 1,060,875 square meters and an average daily sales efficiency of 61.06 yuan per square meter[80] - 8,970 out of 10,264 directly operated stores have obtained "Medical Insurance Designated Retail Pharmacy" qualifications, accounting for 87.39% of the total[80] - The company completed 19 out of 22 M&A transactions in the industry during the reporting period, including the acquisition of 54 stores and 8 clinics for 113 million yuan[83] - In 2023, the company acquired 89 stores for 63 million yuan and 11 pharmacies for 6 million yuan[83] - The company acquired 37 pharmacies for 35 million yuan and 30 stores for 24.6 million yuan in 2023[84] - The company completed the acquisition of 69 stores for 27.19 million yuan and 29 stores for 19.5 million yuan in 2023[86] - The company acquired 55 stores for 36.96 million yuan and 67 stores for 22.4 million yuan in 2023[87] - The company acquired 25 stores for 15.4 million yuan and 15 stores for 17.5 million yuan in 2023[88] - The company's subsidiary, Shijiazhuang Xinxing, acquired a 70% stake in Handan Xinxing Kangheng Pharmacy Chain Co., Ltd. for 16.1 million yuan, involving 35 stores[89] E-commerce and O2O Business - The company's O2O and B2C businesses achieved sales revenue of 1,817.8471 million yuan, with O2O contributing 1,398.7383 million yuan and B2C contributing 419.1092 million yuan[31] - O2O and B2C strategies drove internet sales revenue to 18.18 billion yuan, with O2O contributing 13.99 billion yuan and B2C contributing 4.19 billion yuan[82] - The company's e-commerce business, launched in 2013, integrates online and offline sales through its logistics centers and physical stores[48] - The company's e-commerce platform saw a 40% increase in sales, reaching $2.5 billion in 2023[121] Logistics and Supply Chain - The company's logistics centers are equipped with advanced technologies such as AGV picking systems and Miniload intelligent replenishment systems[46] - The company's supply chain and product structure optimization have improved customer satisfaction and repurchase rates[50] - The company's cross-regional management and replication capabilities are supported by a digital, networked, and intelligent management platform[50] - The company will optimize its product category structure and supply chain management to establish a full-category coverage and differentiated product system[98] Human Resources and Training - The company developed 65 new training courses, conducted 132 offline training sessions, with an average training duration of 70 hours per employee, and recruited nearly 3,000 fresh graduates[34] - The company plans to build a scalable human resource supply system to meet the demands of rapid development, focusing on talent density and career development[98] - The company is addressing human resource challenges by partnering with universities, implementing management trainee programs, and improving employee development and retention strategies[105] - Total number of employees in the parent company and major subsidiaries is 39,652, with 9,920 in the parent company and 29,732 in major subsidiaries[136] - Sales personnel account for 85.1% of the total workforce with 33,751 employees[136] - Educational background of employees: 17,693 have a college degree, 10,315 have a technical secondary school degree, and 5,524 have a bachelor's degree[136] Market and Industry Analysis - In 2023, China's per capita healthcare expenditure was 2,460 yuan, accounting for 9.2% of per capita consumption expenditure[35] - From 2013 to 2022, the sales of China's pharmaceutical retail terminal increased from 10,894 billion yuan to 17,936 billion yuan, with a compound annual growth rate of 8.2%[36] - By the end of 2022, the retail pharmacy terminal market share was 29%, showing a逐年上升 trend[36] - The retail pharmacy industry's连锁化率 reached 57.76% by the end of 2022, with CR10, CR50, and CR100 sales占比分别上升至 30.91%, 44.95%, and 55.83%[38] - The total number of retail pharmacies in China reached 623,300 by the end of 2022, with连锁门店数量 increasing to 359,900[39] - The company's market share in the top 10, top 20, and top 50 pharmacy chains shows significant growth trends[41] - The company's regional focus strategy has led to higher profitability and sales growth compared to industry averages[50] - The company's pharmaceutical retail market concentration in China is lower compared to mature markets like the US and Japan, indicating growth potential[42] - The pharmaceutical retail industry is highly competitive, with large chain enterprises expanding rapidly through mergers and acquisitions, increasing market concentration[101] Corporate Governance and Shareholder Information - The company's registered address is in Changde City, Hunan Province, and its office address is in Changsha City, Hunan Province[10] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603939[13] - The company's financial report was audited by Tianjian Certified Public Accountants, with no significant risks affecting operations reported[4] - The company adjusted its financial statements starting from 2023 due to the implementation of new accounting standards[17] - The company's financial statements for 2023 were audited by Tianjian Certified Public Accountants, with an unqualified opinion issued[197] - The company's revenue recognition process was identified as a key audit matter due to the inherent risk of management manipulating revenue figures[200] - The company's top 10 shareholders did not participate in securities lending or change significantly during the reporting period[193] - The company's controlling shareholder, Ningbo Meishan Free Trade Port Zone Houxin Venture Capital Partnership, was established on September 12, 2006, and focuses on venture capital investments in unlisted enterprises[193] - The company's actual controller, Gao Yi, has not held controlling stakes in any other domestic or foreign listed companies in the past 10 years[195] - The company's actual controller is Gao Yi, who serves as Chairman and President[195] - The largest shareholder, Ningbo Meishan Free Trade Port Zone Houxin Venture Capital Partnership, holds 218,743,980 unrestricted shares[192] - Hong Kong Securities Clearing Company Limited is the second-largest shareholder with 167,741,356 unrestricted shares[192] - The total number of ordinary shareholders at the end of the reporting period was 14,648[188] - The top shareholder, Ningbo Meishan Bonded Port Area Houxin Venture Capital Partnership, held 218,743,980 shares, representing 21.65% of the total shares[189] - Hong Kong Securities Clearing Company Limited held 167,741,356 shares, representing 16.60% of the total shares[189] Strategic Plans and Future Outlook - The company plans to expand its store network through a combination of new openings, acquisitions, and franchising, focusing on regional market share and concentration[97] - The company aims to innovate its business model by integrating online and offline operations, enhancing supply chain systems, and developing new retail e-commerce models[97] - The company will optimize its product category structure and supply chain management to establish a full-category coverage and differentiated product system[98] - The company plans to build a scalable human resource supply system to meet the demands of rapid development, focusing on talent density and career development[98] - The company will enhance its digital service system, focusing on online operation models for people, goods, and venues, and improving operational efficiency[98] - The company aims to become a leading pharmacy chain by focusing on professional services, controlled high-quality products, new retail, and efficient expansion[96] - The company plans to expand into 3 new international markets in 2024, targeting a 25% increase in global market share[121] - A new AI-powered customer service platform will be launched in Q2 2024

让国人身心更加健康 目录 01 02 06 07 63 专题之益路守护 一剂良药之旅 牢筑治理根基 坚守责任底线 锚定精品零售 增进民生福祉 聚力医药可及 守护人民健康 打造专业队伍 成就人才价值 践行绿色理念 共创友好环境 关于本报告 关于我们 董事长寄语 可持续发展管理 附录：GRI 标准与上交 所可持续发展报告指 引章节索引表 公司治理 14 合规运营 18 信息安全与隐私 21 可控精品战略 28 心系民生福祉 33 打造零售网络 39 数字化运营 42 高效物流配送 44 合规雇佣 48 人才培养 49 民主管理 53 员工关怀 53 心理健康 54 职业健康与安全 54 深化环境管理 57 优化资源管理 57 应对气候变化 62 关于本报告 《益丰大药房连锁股份有限公司 2023 年度环境、社会及管治（ESG）报告》（以下简称"本报告"）为益丰大药房连锁股份有限公司连同所有分子公司（以下简称"益丰药房""本公司""公 司"或"我们"）独立发布的第一份环境、社会与公司治理（ESG）报告，旨在向各利益相关方全面呈现本公司 2023 年在 ESG 方面的目标、管理策略、实践与成效。 报告范围 本报告为年 ...

M A K I N G P E O P L E P H Y S I C A L LY A N D M E N TA L LY H E A LT H I E R Content | About this Report | 01 | | --- | --- | | About Us | 02 | | Message from the | 06 | | Chairman | | | Sustainable Development | 07 | | Management | | | Appendix: GRI Standards and | 63 | | SSE Sustainability Reporting | | | Guidelines Content Table | | 12 Featured Topic of Yifeng Pharmacy's Guard of Health Journey to a Good Medicine 13 Consolidating the Foundation of Governance and Adhering to the Bottom Line of Responsi ...

| 项目组成 | 姓名 | 何时成为 | 何时开始 | 何时开始 | 何时开始为 | 近三年签署或 | | --- | --- | --- | --- | --- | --- | --- | | 员 | | 注册会计 | 从事上市 | 在本所执 | 本公司提供 | 复核上市公司 | 益丰大药房连锁股份有限公司 2023 年度会计师事务所履行情况评估报告 益丰大药房连锁股份有限公司（以下简称" 公司"）聘请天健会计师事务所 （特殊普通合伙）（以下简称"天健会计师事务所"）作为公司 2023 年度财务报表 及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公 司选聘会计师事务所管理办法》，公司对天健会计师事务所 2023 年审计过程中的 履职情况进行评估。 经评估，公司认为天健会计师事务所资质等方面合规有效，履职保持独立性， 勤勉尽责，公允表达意见，具体情况如下： | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-032 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 第四届监事会第三十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 监事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日以 电子邮件方式发出第四届监事会第三十二次会议通知，会议于 2024 年 4 月 26 日在湖南省长沙市金洲大道 68 号益丰医药物流园五楼会议室召开，应参加表决 的监事 3 人，实际参加表决的监事 3 人，会议以现场方式召开，本次会议的召集、 召开和表决程序符合有关法律、法规和《公司章程》的规定，会议形成的决议合 法有效。 2、《关于2023年年度报告及其摘要的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及《公 司章程》等规章制度，按照中国证券监督委员会发布的公开发行证券公司信 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥5,970,923,210.35, representing a year-on-year increase of 13.39%[5] - The net profit attributable to shareholders was ¥406,753,106.09, reflecting a growth of 20.89% compared to the same period last year[5] - Basic earnings per share (EPS) stood at ¥0.40, an increase of 19.15% year-on-year[5] - Total operating revenue for Q1 2024 reached ¥5,970,923,210.35, an increase of 13.4% compared to ¥5,266,053,201.98 in Q1 2023[29] - Net profit for Q1 2024 was ¥445,951,883.35, representing a 17.4% increase from ¥379,869,656.04 in Q1 2023[31] - Earnings per share for Q1 2024 were ¥0.40, compared to ¥0.34 in Q1 2023, reflecting a 17.6% increase[31] - Total equity attributable to shareholders reached ¥10,393,858,921.24 in Q1 2024, up from ¥9,804,432,476.56 in Q1 2023, indicating a growth of 6.0%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 49.56%, primarily due to the normalization of medical insurance reimbursements following a public health event[9] - The net cash flow from operating activities decreased to CNY 650,107,205.26 in Q1 2024, compared to CNY 1,288,846,164.43 in Q1 2023, reflecting a decline of approximately 49.5%[34] - Cash inflow from financing activities totaled CNY 1,785,372,000.00 in Q1 2024, with a net cash flow of CNY 1,356,321,367.58, compared to a net outflow of CNY -341,525,797.58 in Q1 2023[36] - The ending cash and cash equivalents balance increased to CNY 4,313,037,671.22 in Q1 2024, up from CNY 2,551,940,192.22 in Q1 2023[36] - The cash flow from operating activities showed a decrease in net cash flow, indicating potential challenges in maintaining operational efficiency compared to the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥26,161,823,616.23, up 8.39% from the end of the previous year[7] - The company's total liabilities amounted to 11,088,641,783.26 RMB, compared to 11,269,471,260.25 RMB at the end of 2023, showing a decrease of about 1.6%[24] - The company's total liabilities as of Q1 2024 amounted to ¥15,093,808,483.45, an increase from ¥13,689,451,532.80 in the previous year[25] - Cash and cash equivalents increased to 5,370,180,357.94 RMB from 3,565,905,738.81 RMB, reflecting a growth of approximately 50.5%[23] - Accounts receivable rose to 2,356,242,795.04 RMB, up from 2,138,274,319.88 RMB, indicating an increase of about 10.2%[23] - Inventory decreased slightly to 3,738,258,397.54 RMB from 3,807,963,660.86 RMB, a decline of approximately 1.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,096[10] - The top ten shareholders held a combined 81.54% of the company's shares, with the largest shareholder owning 21.65%[11] Strategic Initiatives - The company plans to continue its market expansion and acquisition strategy to enhance its competitive position in the industry[18] - In Q1 2024, the company added 701 new stores, including 364 self-built stores, 166 acquired stores, and 171 franchise stores, resulting in a total of 13,920 stores by the end of the reporting period, a net increase of 670 stores[16] - The company completed five acquisition projects during the reporting period, with total acquisition prices amounting to 7,025 million RMB, involving 55 to 67 stores per project[18][19] Research and Development - Research and development expenses for Q1 2024 were ¥9,772,260.99, significantly higher than ¥4,637,452.27 in Q1 2023, marking a 110.0% increase[29] Other Financial Metrics - The company reported non-recurring gains of ¥7,311,972.36 for the period[9] - The return on equity (ROE) was 4.06%, showing a slight increase of 0.21% compared to the previous year[7] - The company reported investment income of ¥14,930,288.87 in Q1 2024, compared to ¥4,603,497.68 in Q1 2023, showing a substantial increase of 224.0%[29] - Other comprehensive income after tax for Q1 2024 was -¥44,204,850.00, a decrease from ¥90,606,909.49 in Q1 2023[31]

一、报告期末主要经营数据 1、主要会计数据及财务指标 | 项目 | | 本报告期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减变动幅度(%) | | 营业收入 | | 5,970,923,210.35 | 13.39 | | 归属于上市公司股东的净利润 | | 406,753,106.09 | 20.89 | | 归属于上市公司股东的扣除非经 | | 399,441,133.73 | 24.26 | | 常性损益的净利润 | | | | | 经营活动产生的现金流量净额 | | 650,107,205.26 | -49.56 | | 基本每股收益（元/股） | | 0.40 | 19.15 | | 稀释每股收益（元/股） | | 0.40 | 19.15 | | 加权平均净资产收益率（%） | | 4.06 | 0.21 | | 本报告期末 | | 上年度末 | 本报告期末 比上年度末 | | | | | 增减变动幅 | | | | | 度(%) | | 总资产 | 26,161,823,616.23 | 24,136,539,194.64 | 8.39 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-038 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置自有资金委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 委托理财概况 1、委托理财目的 为提高公司闲置资金使用效率，在确保日常经营资金需求和资金安全的前 提下，公司及子公司拟利用闲置资金进行短期理财产品投资，以增加公司资金 收益，公司及股东谋取更大的利益。 2、委托理财金额 闲置自有资金不超过人民币 620,000.00 万元。在授权额度范围内，资金可滚 动使用； 3、资金来源 闲置自有资金。 投资种类：使用闲置自有资金投资安全性较高、流动性较好、风险较低的 本金保障类或低风险理财产品； 投资金额：闲置自有资金不超过人民币 620,000.00 万元。在授权额度与时 间范围内，资金可滚动使用； 履行的审议程序：经公司第四届董事会第三十九次会议审议通过，尚需提 交公司股东大会审 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-033 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于 2023 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准益丰大药房连锁股份有限公司公开 发行可转换公司债券的批复》（证监许可〔2020〕593 号），本公司由主承销商中 信证券股份有限公司采用公开发行方式，向社会公众公开发行可转换公司债券数 量 15,810,090 张，每张面值人民币 100 元，共计募集资金 158,100.90 万元，坐扣 承销及保荐费用 1,340.70 万元后的募集资金为 156,760.20 万元，已由主承销商中 信证券股份有限公司于 2020 年 6 月 5 日汇入公司开立的募集资金监管账户。另 减除律师费、会计师费、资信评级费、信息披露及 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告……………第 3—11 页 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕2-300 号 益丰大药房连锁股份有限公司全体股东： 我们鉴证了后附的益丰大药房连锁股份有限公司（以下简称益丰药房公司） 管理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供益丰药房公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为益丰药房公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 益丰药房公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）和《上海证券交易所上市公司自律监管 指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的 规定编制《关于募集资金年度存放与使用情况的专项报告》，并保证其内容真实、 准确、完整， ...